Week of March 18, 2024

Each week we highlight five things affecting the life sciences industry. Here’s the latest.

  • Per CNBC, Nvidia and Johnson & Johnson are collaborating to develop new artificial intelligence applications for surgery, aiming to enhance surgical procedures from pre-op to post-op by integrating AI within devices and platforms.
  • The partnership focuses on using AI to analyze surgical video and automate documentation post-procedure, potentially transforming surgical education and decision-making by making surgical videos more accessible and analyzable for real-time support and training.
  • Per Medtech Insight, President Biden signed a comprehensive executive order to enhance women’s health research, marking the most extensive executive action in this area to date.
  • The executive order aims to bridge research gaps in women’s health, particularly focusing on conditions prevalent or intensifying post-menopause, such as rheumatoid arthritis, heart attacks and osteoporosis.
  • The European Commission has unveiled a comprehensive package of actions aimed at advancing biotechnology and biomanufacturing within the EU, reports EFA News.
  • The proposed actions include stimulating research and innovation, facilitating the use of research infrastructures, and stimulating market demand for bio-based products.
  • Per BioSpace, new graduates are encountering significant difficulties entering the biopharma industry, with increased competition and fewer job openings.
  • The downturn follows a period of layoffs and reduced research investment, leading to a surge in applications per job and a decline in available positions.
  • Schott Pharma is investing $371 million in a new facility in North Carolina to enhance its production of glass and polymer syringes, addressing drug shortages and supporting the growing demand for GLP-1 and mRNA therapies in the U.S., reports Fierce Pharma.
  • This expansion will mark the first U.S. site capable of manufacturing refillable polymer syringes for mRNA medications, aiming to triple its market offerings by 2030.

For more insights in life sciences, check out RSM’s industry outlook.

Source link